Stabilization of quinapril by incorporating hydrogen bonding interactions

Indian Journal of Pharmaceutical Sciences

Volumn 71, Issue 4, 2009, Pages 395-405

  Roy, B N ^a   Singh, G P ^a   Godbole, H M ^a   Nehate, S P ^a  

^a LUPIN LIMITED   (India)

Author keywords

Co crystal; Crystal structure; Quinapril; Solid state; Solvates; Stability; Stabilization

Indexed keywords

2 [2 [(1 ETHOXYCARBONYL 3 PHENYLPROPYL)AMINO] 1 OXOPROPYL] 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID; CARBROMAL; NITROMETHANE; PIPERAZINEDIONE; QUINAPRIL; TROMETAMOL; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BOND; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG IMPURITY; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; SOLID STATE; SOLVATE; THERMOSTABILITY; X RAY DIFFRACTION;

EID: 71049177449     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: 10.4103/0250-474X.57288     Document Type: Article

References (41)

1. Steinberg SM, Bada JL. Peptide decomposition in the neutral Ph region via the formation of diketopiperazines. J Org Chem 1983;48:2295-2298
2. Chimanlal G, Ronals TB. Kinetics of diketopiperazine formation using model peptides. J Pharm Sci 1998;87:283-288
3. Purdie JE, Benoiton NL. Piperazinedione formation from esters of dipeptides containing glycine, alanine and sarcosine: The kinetics in aqueous solution. Chem Soc Perkin Trans 2. 1973;13:1845-1852
4. Steinberg SM, Bada JL. Diketopiperazine formation during investigations of aminoacid racemization in dipeptides. Science 1981;213:544-545
5. Hoefle ML, Klutchko S. Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids. US Patent No. 4,344, 949, August 17, 1982.
6. Jiyon TS, Jiefurii EB, Jiyon AR. N-(substituted aminoalkanoyl) heterocyclic compounds. GB Patent No. 2,095,252, September 29, 1982
7. Patchett AA, Wu MT. Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same. EP Patent No. 0,065,301, November 24, 1982.
8. Guo Y, Byrn SR, Zografi G. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci 2000;89:128-143
9. Ulrich JG. The importance of solvates. In: Hilfiker R, editor. Polymorphism in pharmaceutical Industry. Weinheim: Wiley-VCH; 2006. p. 211-233
10. Brittain HG. Polymorphism and solvatomorphism 2006. J Pharm Sci 2007;97:3611-3636
11. Baure J, Morley J, Spanton S, Leusen FJ, Henry R, Hollis S, et al. Identification, preparation, and characterization of several polymorphs and solvates of terazosin hydrochloride. J Pharm Sci 2006;95:917-928
12. Rollinger JM, Burger A. Physicochemical characterization of hydrated and anhydrous crystal forms of amlodipine besylate. J Thermal Anal Calorimetry 2002;68:361-372
13. Petit S, Coquerel G. Mechanism of several solid-solid transformations between dihydrated and anhydrous copper(II) 8-hydroxyquinolinates. proposition for a unified model for the dehydration of molecular crystals. Chem Materials 1996;8:2247-2258
14. Li J, Guo Y, Zugrufi G. Effects of a citrate buffer system on the solidstate chemical stability of lyophilized quinapril preparations. Pharm Res 2002;19:20-26
15. Harris M, Hokanson G, Murthy K, Reisch R, Waldman F. Stabilized compositions. US Patent No. 4,743,450, May 10, 1988.
16. Sherman BC. US Patent No. Pharmaceutical compositions comprising quinapril magnesium. 6,531,486, March 11, 2003.
17. Klokkers K, Kramer KT, Fischer W, Sendl-Lang A. Matrix controlled transdermal system for stabile derivatives of ace inhibitors. US Patent Application No. 20040052835, March 18, 2004.
18. Klokkers K, Helfrich M, Nink J. Matrix controlled transdermal system for stabile derivatives of ace inhibitors. WO 2007065638, June 14, 2007.
19. Li J, Guo Y, Zografi G. The solid-state stability of amorphous quinapril in the presence of beta cyclodextrins. J Pharm Sci 2002;91:229-243
20. Goel OP, Krolls U. Crystalline quinapril and a process for producing the same. US Patent No. 4,761,479, August 2, 1988.
21. Singh GP, Rawat GS, Dhake VN, Nehate SP. Crystalline form of quinapril hydrochloride and process for preparing the same. EP1572661, September 14, 2005.
22. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. Pharmaceutical Co-crystals. J Pharm Sci 2006;95:499-516.
23. Etter MC, Adsmond DA. The use of co-crystallization as a method of studying hydrogen bond p of 2-aminopyridine. J Chem Soc Chem Commun 1990;589-591
24. Etter MC. Graph-set analysis of hydrogen-bond patterns in organic crystals. Acta Crystallogr B 1990;46:256-262
25. Etter MC, Urbanczyk-Lipkowska Z, Zia-Ebrahima M, Panunto TW. Hydrogen bond directed co crystallization and molecular recognition properties of diarylureas. J Am Chem Soc 1990;112:8415-8426
26. Carl HG, Hans PH On the inclusion of solvent molecules in the crystal structures of organic compounds. Acta Crystallogr B 2000;56:525-534
27. SenthilKumar VS, Nangia A. Molecular complexes of some mono- and dicarboxylic acids with trans-l,4,-dithiane-l,4-dioxide. Crystal Growth Design 2002;2:325-328
28. Desiraju GR. Crystal and co-crystal. Crystal Engg Commun 2003;5:466-467
29. Almarsson O, Bourghol HM, Peterson M, Zaworotko MJ, Moulton B, Rodriguez-Hornedo N. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen. US Patent Appl. 20070059356, March 15, 2007.
30. Jennings SM. Preparation of quinapril hydrochloride. US patent No. 6,858,735, February 22, 2005.
31. Monsalvatje LM, Bartra SM, Tomas NJ, Puig TS. Process for obtaining quinapril hydrochloride and solvates useful for isolating and purifying quinapril hydrochloride. US patent No. 6,617,457, September 9, 2003.
32. Sheldrick GM. SAINT 5.1 ed., Siemens Industrial Automation Inc., Madison, WI. 1995
33. SADABS, empirical absorption Correction Program; Göttingen, Germany, University of Göttingen: 1997.
34. Sheldrick GM. SHELXTL reference manual: Version 5.1, Madison, Bruker AXS, WI. 1997.
35. Sheldrick GM. SHELXL-97: Program for Crystal Structure Refinement; Göttingen, Germany, University of Göttingen: 1997.
36. Spek AL. PLATON for MS-Windows. Journal of Applied Crystallography 2003;36:7-13.
37. Farrugia LJ. Ortep-3 for Windows. J Applied Crystallogr 1997;30:565-665
38. Macrae CF, Edgington PR, McCabe P, Pidcock E, Shields GP, Taylor R, et al. Mercury: visualization and analysis of crystal structures. J Applied Crystallogr 2006;39:453-457
39. Hausin RJ, Codding PW. Molecular and crystal structure of MDL27,467A Hydrochloride and Quinapril Hydrochloride, Two Ester Derivatives of Potent Angiotensin Converting Enzyme Inhibitors. J Med Chem 1991;34:511-517
40. The Cambridge Structural Database (CSD)- The world repository of small molecule crystal structures The Cambridge Crystallographic Data Centre, Copyright © 2004-2008.
41. Boeyens JCA. Calculation of ring puckering parameters. J crystallogr Mol Structure 1978;8:317.